CytoReason
@Cytoreason
Followers
578
Following
316
Statuses
574
CytoReason’s computational disease model, used by 5/10 top pharma leaders, minimizes need for animal trials and makes human trials more accurate and focused.
Israel
Joined February 2018
CytoReason is #hiring. We're looking for #backend and #fullstack developers, #bioinformaticians, #immunologists and more. Find out more and apply here:
0
0
1
Tania Dubovik Perets with Elina Starosvetsky, Yasmin Admon, Shai @shenorr & others publish groundbreaking study showing immune system’s adaptability and providing evidence that interactions between immune cell types facilitate evolution of immune traits.
0
0
3
CytoReason raises $80M in Series B from @nvidia, @pfizer, @thermofisher and others. This means we'll be able to cover more sub-populations, strengthen precision of our disease models and empower more decision-makers with AI tools for their R&D.
0
0
1
Read more about CytoReason's new data collaboration agreement with @CrohnsColitisFn. We'll be integrating the foundation's vast datasets with CytoReason’s #IBD disease models. Read more about it here:
0
0
2
@Cytoreason signs data collaboration with @CrohnsColitisFn Foundation to advance IBD. We'll be incorporating CCF's massive datasets - with thousands of patient intestinal biopsies and comprehensive real-world data - into our pre-computed disease models.
0
0
2
New episode of "Tech on Drugs" with Prof. Eran Segal from Weizmann and co-founder Prof. Shai @shenorr - addressing precision nutrition, large-scale longitudinal data, microbiome studies, and more. Fulle episode here:
0
0
1
In 2023 - 21 CytoReason employees, published 19 papers in 16 different publications - Nature Immunology, Nature Cancer, Nature Communications, Nucleic Acids Research, CellReports, &more. More here: #Immunology #pharma
@CellReports
@NAR_Open
0
0
3
@sanofi's been leveraging AI and data analytics across multiple R&D initiatives - from unlocking previously undruggable targets, to driving in silico clinical trials. It's a privilege to partner with them as they shape the future of drug development.
0
0
1
Interview with CEO David Harel about some of the major scientific and commercial challenges our industry faces, and about one tech company's attempt to make things (a little bit) better.
0
1
2
Proud of our Chief Scientist Shai @shenorr for contributing to this new study by Benguigui & Cooper et. al, now published in Cancer Cell and highlighted in Nature Reviews Immunology. #CancerResearch #Oncology
0
2
3
Our team's research published in @CellReports. Introducing 'Disruption Networks', a personalized computational network framework for system-level understanding of disease mechanisms & drug response, exposing differential regulation @ individual level.
0
3
4
@DeepPharmaUK lists @Cytoreason as one of TOP-50 companies making significant contributions to #pharmaceutical and #healthcare sectors.
0
0
0
Another TOD episode is out! This time with serial biotech entrepreneur @YanayOfran. Yanay spoke to Shai @shenorr about the barriers to #PrecisionMedicine and about the power of AI-designed antibodies. #biotech #drugdiscovery
0
1
2
In this episode of "Tech on Drugs (TOD), our Chief Medical Officer Yehuda Chowers talks about immunogenicity, population models, and the next generation of drug development. #Biotechnology #Pharmaceutical
0
0
4
Our new podcast "Tech on Drugs" is live. Host Shai @shenorr speaks to top scientists and execs about #pharma's digital transformation. First guest - renowned epidemiologist @RanBalicer. #biotech #Pharmaceutical #DrugDiscovery
0
1
6
#2022 was the year we scaled up. Here are some highlights. Can't wait for 2023! #Biotech #Pharmaceutical #AI
0
2
6
Using our computational disease models to evaluate novel disease mechanisms for #influenza with @PoolbegPharma. Potential to yield drug targets for treatments more efficiently than with traditional reductionist analysis & #drugdiscovery techniques.
0
2
6